We have characterized the action of the tachykinin NK2 receptor antagonist
nepadutant (c{[(beta-D-GlcNAc)Asn-Asp-Trp-Phe-Dpr-Leu]c(2 beta-5 beta)}) in
the human isolated ileum, colon and urinary bladder. Nepadutant (30-1000 n
M) competitively antagonized neurokinin A- or [beta Ala(8)]neurokinin A-(4-
10)-induced contractions in all tissues, with p K-B = 8.3 (ileum and colon)
and pK(B) = 8.5 (bladder). In contrast, the nonpeptide tachykinin NK2 rece
ptor antagonist SR 48968 (or (S)-N-methyl-N [4-acetylamino-4-phenylpiperidi
no)-2-(3,4-dichlorophenyl) butyl] benzamide) (30-1000 nM) produced insurmou
ntable antagonism in all preparations. The tachykinin NK2 receptor blockade
produced by nepadutant in the colon was fully reversed by washout, whereas
that produced by SR 48968 was not. Nepadutant (1 mu M) greatly reduced (by
70-80%) the nonadrenergic noncholinergic (NANC) contractile off-response e
volved by electrical field stimulation in the human ileum, and almost aboli
shed it in the presence of the tachykinin NK1 receptor antagonist GR 82334
(or: [[(S,S) Pro-Leu (spiro-gamma-lactam)](9,10),Trp(11)]Physalaemin(1-11))
(1 mu M). The present results show that nepadutant is a potent, competitiv
e and reversible antagonist at human tachykinin NK2 receptors and provide f
urther evidence that tachykinins act as excitatory NANC neurotransmitters i
n the human small intestine. (C) 2000 Elsevier Science B.V. All rights rese
rved.